Index: EPR Wellness Coverage Hub · Ozempic Rewrote the Wellness Industry · How Diet PR Changed After Ozempic · What Diet Brands Got Wrong After Ozempic
Updated June 24, 2026.
The Diet Brand Reset: WW, Noom, Jenny Craig in the GLP-1 Era
Five diet brands faced the GLP-1 reset between 2022 and 2026. Two repositioned. Two struggled. One filed for bankruptcy. The marketing strategies that defined the diet category for forty years stopped working — and the brands that survived rebuilt around clinical authority, behavioral coaching, or strategic pivots into adjacent categories.
The diet category's transformation between 2022 and 2026 is one of the cleanest case studies in modern consumer-category disruption. The same five brands that defined the category in 2020 — WW (formerly WeightWatchers), Noom, Jenny Craig, Nutrisystem, and Herbalife — faced the same structural shock from GLP-1 medications. Their responses diverged sharply. The lessons compound.
WW (WeightWatchers): The Clinical Pivot
WW executed the most strategically coherent diet-category response to GLP-1. The brand's 2023 acquisition of Sequence — a telehealth platform that prescribes GLP-1 medications alongside behavioral support — created an integrated clinical-and-behavioral product that no other diet brand offered. The repositioning around "weight health" rather than "weight loss" — and the explicit acknowledgment that GLP-1 medications are part of the modern weight-management toolkit — moved the brand from competing-with-GLP-1 to complementing-with-GLP-1.
The business transition has been difficult. The legacy WeightWatchers points-and-meetings business declined materially as members migrated to medications. The Sequence-anchored clinical platform required workforce restructuring, technology investment, and a brand reset that the broader Wall Street narrative had not yet fully absorbed by 2026. The strategic logic, however, remained the strongest case study in the category. WW's eventual fate as a public company is still being written; the playbook it executed is the reference case for diet-brand GLP-1 navigation.
Noom: The Behavioral Coaching Repositioning
Noom's response leveraged the brand's pre-existing behavioral-coaching authority. Rather than pivoting into the clinical-prescribing space, Noom doubled down on behavioral coaching as the complementary discipline to GLP-1 medications — articulating a clear case for psychology-led habit formation alongside medication use rather than as an alternative to it.
The brand introduced explicit GLP-1 compatibility messaging across its app experience, integrated medication-cycle support into its coaching protocols, and built editorial content around the question of behavior change inside the GLP-1 era. The strategic positioning held — Noom remained a category-relevant brand inside the new addressable market rather than competing for the shrinking traditional-dieting market.
Jenny Craig: The Collapse
Jenny Craig's response was the category's most-cited failure case. Multiple structural issues — declining membership, supply-chain stress from the meal-delivery model, leverage pressure from prior ownership structures, and a brand identity that hadn't been updated for the digital-first consumer — converged with the GLP-1 disruption to produce a 2023 wind-down of U.S. operations and brand-asset sale.
The communications lessons from Jenny Craig's collapse compound across the category. The brand's narrative-management of the wind-down, the executive communications gaps, and the lack of public strategic response to GLP-1 disruption all illustrated what happens when a legacy diet brand faces structural shock without crisis-communications infrastructure. The brand assets have continued to surface in subsequent ownership configurations; the structural lesson stands.
Nutrisystem: The Niche-Pressure Cycle
Nutrisystem faced sustained competitive pressure from telehealth GLP-1 providers, meal-delivery competitors with stronger DTC infrastructure, and the broader question of whether structured meal-delivery weight management remains relevant in a GLP-1 era. The brand has navigated the disruption from a smaller market-share position than WW, with less clear strategic differentiation than Noom — and the ongoing question of whether meal delivery alone is a defensible category position in the GLP-1 landscape.
The 2024–2026 trajectory has seen Nutrisystem operate as a smaller niche brand inside a category structurally moving away from its core offering. The strategic options — clinical integration, behavioral-coaching emphasis, premium meal-delivery repositioning — remain available but require investment the brand's parent-company structure may or may not support.
Herbalife: The MLM and GLP-1 Convergence
Herbalife's category position is structurally different from the four traditional diet brands. The multi-level marketing model, the supplement-and-meal-replacement product mix, and the international distribution architecture make Herbalife's response to GLP-1 distinct from a U.S. consumer-brand response. The brand has faced regulatory pressure across multiple jurisdictions, ongoing scrutiny of its MLM economics, and the broader question of supplement-and-meal-replacement relevance in the GLP-1 era.
The communications challenge for Herbalife is twofold — managing the legacy MLM-and-supplement reputation surface while addressing the substantive consumer question of whether the products serve a relevant role in modern weight management. The 2024–2026 period has not seen a strategic repositioning at the scale WW executed. The brand's long-term trajectory remains an open question.
The Unifying Lesson
Across the five brands, the same pattern recurs. The brands that articulated a clear complementary value proposition to GLP-1 medications — clinical integration, behavioral coaching, post-medication maintenance — survived and repositioned. The brands that competed against GLP-1 or denied the structural shift lost ground, share, and in the most severe cases, ownership continuity.
The deeper lesson: in any consumer-category disruption, the brands with sophisticated reputation infrastructure and crisis-communications discipline respond within months. The brands without it respond within years — or never. The diet category's 2022–2026 reset is the clearest recent case study, and the structural lessons apply far beyond weight management.
Frequently Asked Questions
Which diet brand handled the GLP-1 era best?
WW's clinical pivot via Sequence is the most strategically coherent case study, though the business transition has been difficult. Noom's behavioral-coaching repositioning is the second-most-cited example.
What happened to Jenny Craig?
Jenny Craig wound down U.S. operations in 2023 amid converging pressures — declining membership, supply-chain stress, ownership-structure leverage, and the broader GLP-1 disruption. The brand assets have continued to surface in subsequent ownership configurations.
Is the diet category dead?
No — but it's structurally different. The addressable market for behavioral coaching, clinical integration, and post-GLP-1 maintenance is real and growing. The market for legacy diet-only programming is contracting.
Which diet brand is most likely to disappear next?
EPR doesn't forecast individual brand fates, but the structural pattern is clear: brands without complementary GLP-1 positioning, without clinical or behavioral authority differentiation, and without disciplined reputation infrastructure are at materially elevated risk.
What should new entrants build?
Clinical-and-behavioral integrated platforms with explicit GLP-1 compatibility, transparent outcomes data, and the editorial infrastructure that produces favorable AI engine synthesis. The market opportunity for behaviorally-anchored maintenance alongside GLP-1 medications is materially larger than the legacy diet-only opportunity it's replacing.
